Doxorubicin
Adriamycin · Anthracycline
Experimental podocyte model; clinical proteinuria rare.
GLOM
MildOpen →
EGFR TKI
Erlotinib
Tarceva · ERL
An oral EGFR TKI rarely linked to minimal-change-type glomerular disease, AKI, and dehydration from GI toxicity.
MildEGFR TKI · approved 2004
EGFR-mutant non-small cell lung cancerLocally advanced/metastatic pancreatic cancer (with gemcitabine)
Signature kidney injury
Glomerular Injury / Proteinuria
Glomerular disease (including minimal-change-type nephrotic syndrome) and acute kidney injury are reported rarely, at the case level; pharmacovigilance data show measurable disproportionality signals for AKI/renal failure (and rare TMA) but no robust trial-based incidence.
Source: Crosnier et al., Cancers 2021
Mechanism of kidney injury
Proposed mechanisms relate to EGFR signaling in podocytes and tubular cells. Case reports describe nephrotic-range proteinuria with minimal-change/minor glomerular abnormalities (podocyte foot-process effacement on a near-normal light-microscopic background) that remit on drug withdrawal, suggesting a drug-associated podocytopathy; acute tubular injury/AKI is also described, frequently compounded by volume depletion from EGFR-TKI-associated diarrhea and anorexia, and rare thrombotic microangiopathy has been signaled.
Clinical presentation
Proteinuria (occasionally nephrotic-range with edema and hypoalbuminemia) and/or a rising creatinine. Diarrhea, mucositis, and reduced intake commonly contribute a prerenal/ischemic component with concentrated urine and low urine output.
Onset
Weeks to months after starting therapy; proteinuria/creatinine typically improve over weeks after discontinuation in reported cases.
Reversibility
Reversible
Anticancer mechanism
Reversible, ATP-competitive EGFR tyrosine kinase inhibitor that blocks EGFR autophosphorylation and downstream RAS/MAPK and PI3K/AKT proliferative signaling. Used in EGFR-mutant non-small cell lung cancer and (with gemcitabine) advanced pancreatic cancer.
Management
Evaluate proteinuria and renal function and consider biopsy for nephrotic syndrome or unexplained AKI; for significant nephrotic syndrome or AKI, hold or discontinue erlotinib, which often leads to remission. Provide supportive care, volume repletion, and RAAS blockade for proteinuria as appropriate.
Risk factors
- Pre-existing chronic kidney disease
- Volume depletion from EGFR-TKI-associated diarrhea/anorexia
- Concurrent nephrotoxins
Prevention
- Baseline and periodic urinalysis/proteinuria and creatinine checks
- Aggressive management of diarrhea and maintenance of hydration
Note · Renal toxicity is uncommon and largely case-based; a published case of gefitinib-associated minimal-change nephrotic syndrome was successfully switched to erlotinib without recurrence, underscoring that severe glomerular events are idiosyncratic rather than uniform across EGFR TKIs.
Clinical depth
Renal dose adjustment
No specific dose reduction is established for renal impairment (erlotinib is hepatically metabolized via CYP3A4/1A2 and biliary-excreted); use caution in severe impairment as renal data are sparse, and manage GI-driven volume depletion proactively. The pancreatic-cancer regimen pairs it with gemcitabine, which has its own renal considerations.
Dialyzability & ESKD dosing
Not appreciably dialyzable—highly protein-bound (~93%), lipophilic, with predominantly hepatic clearance and minimal renal elimination; hemodialysis is not expected to remove meaningful drug.
Differential diagnosis
Distinguish drug-associated podocytopathy/minimal-change disease (abrupt nephrotic syndrome remitting on withdrawal) from paraneoplastic glomerulopathy of the underlying cancer, and separate true intrinsic AKI from prerenal azotemia caused by diarrhea/anorexia (low urine sodium, responds to volume). Consider rare erlotinib-associated TMA when AKI is accompanied by hemolysis and thrombocytopenia.
Monitoring
- Urinalysis/urine protein at baseline and periodically
- Serum creatinine/eGFR each cycle, more often during diarrhea
- Volume status and electrolytes during GI toxicity
Key trials & series
- Moore JCO 2007 erlotinib-gemcitabine pancreatic registration trial
- Maruyama Intern Med 2015 EGFR-TKI minimal-change nephrotic case
- Crosnier Cancers 2021 VigiBase EGFR renal-safety pharmacovigilance
Clinical pearls
- Most erlotinib 'renal' events are prerenal from diarrhea/anorexia—rehydrate before assuming intrinsic injury.
- True nephrotic syndrome is a rare minimal-change-type podocytopathy that usually remits when the drug is stopped.
- EGFR-TKI glomerular reactions are idiosyncratic: gefitinib-induced disease has been tolerated on a switch to erlotinib.
- Keep rare thrombotic microangiopathy on the differential if AKI comes with hemolysis and low platelets.
Where it strikes
Nephron segments
Glomerulus
Filtration barrier (podocytes + endothelium)
Proximal Tubule
Bulk reabsorption + drug uptake (OCT2, OATs)
Injury signatures
Glomerular Injury / ProteinuriaAcute Tubular Necrosis
Beyond the kidney
Class-level context for the major non-renal toxicities of egfr tkis.
Dermatologic
Rash, HFS, SJS/TEN, vitiligo
- Acneiform rash, paronychia
Gastrointestinal
Diarrhea, colitis, mucositis, perforation
- Diarrhea
Pulmonary
Pneumonitis, ILD, effusions, hypertension
- Interstitial lung disease (EGFR TKIs)
Evidence
6 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkMinimal change nephrotic syndrome associated with gefitinib and a successful switch to erlotinib.Maruyama K et al. · Intern Med 2015 · PMID 25832950Documents EGFR-TKI-associated minimal-change nephrotic syndrome and tolerated erlotinib rechallenge.PMIDErlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.Moore MJ et al. · J Clin Oncol 2007 · PMID 17452677Registrational pancreatic-cancer trial; reference for the gemcitabine-erlotinib regimen and its toxicity context.PMIDRenal Safety Profile of EGFR Targeted Therapies: A Study from VigiBase, the WHO Global Database of Individual Case Safety Reports.Crosnier A et al. · Cancers (Basel) 2021 · PMID 34885014Pharmacovigilance disproportionality signals for erlotinib including AKI, renal failure, and TMA/HUS.PMIDRenal toxicity of anticancer agents targeting HER2 and EGFR.Cosmai L et al. · J Nephrol 2015 · PMID 26341657Onconephrology review of EGFR-directed renal toxicity, covering erlotinib.PMIDNew drug toxicities in the onco-nephrology world.Perazella MA · Kidney Int 2015 · PMID 25671763Onconephrology review summarizing proteinuria, AKI, and glomerular effects of targeted agents including EGFR TKIs.PMIDOnconephrology: mitigation of renal injury in chemotherapy administration.Selamet U et al. · Curr Opin Nephrol Hypertens 2023 · PMID 38095483Contemporary onconephrology review of targeted-therapy renal toxicities and mitigation strategies.
Related agents
Other agents sharing the same signature kidney injury.